No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Daliresp (roflumilast) is a prescription medication used to treat chronic obstructive pulmonary disease (COPD). It is a phosphodiesterase-4 (PDE-4) inhibitor, which works by reducing inflammation in the lungs. Daliresp is used in combination with other COPD medications to reduce the risk of exacerbations and improve lung function. It is available in tablet form and is taken once daily.
The Daliresp market is a subset of the larger respiratory drugs market, which includes medications used to treat a variety of respiratory conditions, such as asthma, COPD, and cystic fibrosis. The market is highly competitive, with a number of companies offering similar products.
Some of the companies in the Daliresp market include AstraZeneca, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more
